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paravalvular regurgitation was mild or absent in all. The 30 day
mortality was 34%, cardiac¼13.6% (LVOTO, LV perforation, AV block,
MI) and non-cardiac¼20.4% (multiorgan failure, pneumonia,
bleeding, stroke). NYHA class at baseline was 3 or 4 in 98%. At follow-
up (mean 5 months, range 1-32), all survivors were in NYHA class I or II
at 30 days (n¼12) and at 1 year (n¼6).
CONCLUSIONS This ﬁrst large analysis of TMVR with balloon
expandable valves in patients with severe MAC reveals that the
procedure is feasible but may be associated with signiﬁcant adverse
events. This strategy might be an alternative for selected inoperable
patients without other treatment options. Studies are needed to
determine how patients should be screened to identify optimal
candidates for this challenging procedure and improve clinical
outcomes.
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BACKGROUND Redo surgery for degenerated mitral valve bio-
prostheses or failing surgical mitral rings may be high risk in-
terventions, especially in elderly patients with comorbidities.
Transcatheter mitral valve-in-valve implantation procedures are
constantly evolving.
METHODS Between November 2010 and June 2015, 22 patients (71.2 
13.4 years; 7 men [31.8%]; 16 in NYHA class III, 6 in NYHA class IV; log.
EuroScore 33.8  17.1%; STS score 11.5  9.2%) underwent a trans-
catheter procedure due to a degenerated bioprosthesis (n¼14) or a
failing surgical ring (n¼8) in the mitral position. Using the SAPIEN
(n¼1), SAPIEN XT (n¼15) and SAPIEN 3 (n¼6) prostheses, access routes
were transapical (n¼13), transfemoral-transseptal (n¼8) and trans-
jugular-transseptal (n¼1). Indications for the interventions were
mitral stenosis (n¼7) and mitral regurgitation (n¼15).
RESULTS The mean time interval between index surgery and the
transcatheter procedure was 8.8  4.6 years. Procedural success was
100%. There was one major vascular complication (4.5%) and one
acute kidney injury (4.5%) after the procedure. Three patients (13.6%)
had a stroke. New pacemaker implantation was not required in any
patient. The degree of post-interventional mitral regurgitation was
none or mild in all cases but one who had mild-to-moderate para-
valvular regurgitation. Final mean transmitral pressure gradient was
6.2  2.1 mmHg. Haemodynamically, signiﬁcant reductions in capil-
lary wedge and left atrial pressure were observed immediately after
the procedure (24.3  8.6 mmHg vs. 18.1  6.0 mmHg [p < 0.05] and
22.9  8.3 mmHg vs. 13.8  5.9 mmHg [p < 0.05], respectively). Thirty-
day mortality was 9.1% (2/18). One patient who was treated as a life-
saving measure in a cardiogenic shock situation with multiple organ
dysfunction syndrome died 5 days after the procedure due to septic
shock, the second patient died 10 days after the procedure due to
pneumonia (patient refused an intubation and mechanical
ventilation).
CONCLUSIONS Our initial experience showed that transcatheter im-
plantation of aortic-valve prostheses for degenerated bioprostheses or
surgical rings in the mitral position is feasible and safe, regardless of
valve type or access route. Hemodynamics were acutely improved.
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BACKGROUND Transcatheter percutaneous mitral valve repair with
the MitraClip procedure continues to be utilized in higher risk patient
groups and more complex mitral valve anatomy. Patients with chronic
kidney disease (CKD) represent a high risk subset of patients generally
excluded from randomized clinical trials. Patients with CKD were
excluded in the initial randomized clinical trials (EVEREST I/II) eval-
uating the MitraClip procedure. The aim of the current multi-center
registry is to determine acute and short-term MitraClip procedural
outcomes in patients with CKD.
METHODS Patients are being enrolled from 4 clinical sites using the
MitraClip in a commercial manner. To date, 80 patients with severe (3-
4þ) mitral regurgitation (MR) were included in this analysis. CKD was
deﬁned as a GFR less than 40 ml/min as estimated by the Cockcroft-
Gault formula. Acute procedural success was deﬁned as implantation
of at least one MitraClip with a reduction of MR severity to 2þ or less.
The acute and short term functional class and NYHA were then
analyzed.
RESULTS Thirty-nine patients were included in the CKD group, of
which four of these were on hemodialysis. Mean creatinine was 1.1 
0.07 in patients with preserved renal function versus 2.4  0.3 mg/dl
in the patient’s with CKD. Patients with CKD had more history of
coronary artery disease and lower hemoglobin levels. There were no
signiﬁcant differences in other baseline demographics in the two
groups (Table 1). Acute procedural success was achieved in all
patients. On average there were 1.7  0.12 clips implanted in the
non-CKD vs 1.6  0.09 clips in the CKD group (p ¼ 0.57). The
discharge trans-mitral gradient did not differ between the groups
(3.9  0.4 vs 4.0  1.1 mmHg, p ¼ 0.72). There was no change in
creatinine from pre- to post-procedure in the two groups. At one
month follow-up, there was no difference in NYHA class and MR
grade between the two groups.
CONCLUSIONS In this real-world registry, patients with existing renal
dysfunction had acute and short-term outcomes that were similar to
patients who did not have impaired renal function. In this ongoing
registry, further analysis will be performed evaluating procedural
differences, complications, mid-term outcomes, and survival in pa-
tients with and without CKD.No CKD
n[41CKD
n[39 P ValueAge (yr) 72  1.5 77  2.1 0.1
Male (%) 24 (59) 22 (56) 0.85HTN (%) 28 (70) 30 (77) 0.49DM (%) 9 (23) 15 (40) 0.12CAD (%) 19 (46) 29 (74) 0.01On HD (%) 0 (0) 4 (11) 0.04EF >55% (%) 26 (63) 21 (54) 0.39Creatinine (mg/dL) 1.1  0.07 2.4  0.3 0.0001
Hemoglobin (g/dl) 13.0  0.2 11.5  0.2 0.00001
No of Clips 1.7  0.12 1.6  0.09 0.44
Discharge TMG
(mmHg)3.9  0.4 4  1.1 0.72OneMo NYHA > III (%) 3 (7) 2 (5) 0.69One Mo MR >[ 3D
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